Printed from the IBC Life Sciences Web site on February 3, 2012 9:00 PM ET.
Page location: http://www.ibclifesciences.com/AsiaTIDES/overview.xml
February 28 - March 01,--> 2012 · Sheraton Miyako Hotel · Tokyo, Japan
Join our priority contact list and receive the latest event news.
Clinical Development of Mipomersen, an Antisense Second-Generation Oligonucleotide Targeting Apolipoprotein B
Tejdip Singh, M.D., Medical Director, Global Patient Safety and Risk Management, Genzyme Corporation, USA
Oligonucleotide and Delivery Platform Optimization Strategies for siRNA Drug Development
Laura Sepp-Lorenzino, Ph.D., Senior Director, RNA Therapeutics, Merck & Co., Inc., USA
Recent Advances in Routes of Delivery for Peptide Pharmaceuticals
Nozer Mehta, Ph.D., Vice President, R&D, UniGene Laboratories, Inc., USA
Overview of Peptide Therapeutics and Vaccines in Development
Yuji Heike, M.D., Ph.D., Chief of Medical Staff, Department of Medical Oncology, National Cancer Center Hospital, Japan
Evolution and Development of GLP-1 Based Therapeutics
Andrew A. Young, M.D., Ph.D., Vice President, Head, Enterendocrine Biology, GlaxoSmithKline, USA
A Pivotal Year for Oligonucleotide Therapeutics
Arthur A. Levin, Ph.D., Chief Development Officer, Santaris A/S, USA and Denmark
RaPID Selection of a New Class of Peptide Drug Leads against Various Therapeutic Targets
Hiroaki Suga, Ph.D., Professor, Chemical Biology and Biotechnology Lab, The University of Tokyo, Japan
The conference will be conducted in English without translation.
The best forum to gain applied and basic knowledge, build your collaborative network, and learn skills to move your projects forward in one of today's hottest research areas
AsiaTIDES continues to be the premier forum to get a comprehensive update, meet key players and increase your knowledge of the oligonucleotide- and peptide-based therapeutics fields.
The faculty list for the 2012 program is the strongest yet, with more representation from big pharma than ever before. Hear new data and strategic perspectives from Merck, Genzyme, and GlaxoSmithKline, including three presentations from Glaxo on a peptide project and their assessments of both the oligo and peptide landscape. Plus hear from Isis, Novo Nordisk, Ipsen, Quark, Alnylam, Santaris, Tekmira and a host of other important companies you need to follow to stay abreast of this field.
"My first time attending AsiaTIDES was very enjoyable. AsiaTIDES brought my company meaningful information widely. I was very happy meeting the delegates from American/Europe, and Asian companies… The balance was good in oligonucleotide and peptide. I enjoyed conference hopping." - Dr. Yoshitsugu Akiyama, Senior Research Scientist, NOF Corporation, Japan
In-Depth Tutorials to Increase your Knowledge:
"The TIDES series of conferences is an indispensable catalyst for the industry, bringing expert people together to share their knowledge and address common issues, ensuring that we can grow our respective enterprises and help TIDES-based medicine flourish. A unique opportunity to hear the latest developments in the field across all disciplines and hear how industry colleagues are rising to the challenges. Over and above the informative presentations will be the invaluable networking with experienced and knowledgeable individuals."
- Allison L. Morgan, Vice President, Clinical Research and Development, Prosensa Therapeutics, The Netherlands
"At TIDES I have the opportunity to meet clients and industry collaborators, to educate myself enormously about current projects, new products and new potential therapies. I think we will be part of the breakthrough in taking medicine that step further in treating complicated and pernicious diseases which still remain today incurable. (I believe)… the combination of peptides and oligonucleotides represent a combined ingredient class in therapeutics which will break the back of cancer and other diseases that have plagued mankind for all our history. It's a special, special event. I always enjoy myself and find it incredibly enriching and rewarding."
- Lester Mills, Ph.D., MBA, Chief Marketing Officer, Bachem Holding AG, Switzerland